Skip to main content

Open-Label, Multicenter, Dose-Escalation Expansion Phase IB study to Evaluate Safety, Pharmacokinetics, and activity of BET Inhibitor RO6870810, Given as Mono- and combination Therapy to patients with Advanced Multiple Myeloma

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

F. Hoffmann-La Roche Ltd

Start Date

April 2, 2018

End Date

June 9, 2020
 

Administered By

Duke Cancer Institute

Awarded By

F. Hoffmann-La Roche Ltd

Start Date

April 2, 2018

End Date

June 9, 2020